Cargando…

Exercise-Induced Changes in Tumor Growth via Tumor Immunity

Immunity in the tumor microenvironment plays a central role in tumor development. Cytotoxic immune cells act against tumors, while tumors manage to trigger immunosuppressive mechanisms for defense. One bout of physical exercise acutely regulates the immune system inducing short-term redistribution o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spiliopoulou, Polyxeni, Gavriatopoulou, Maria, Kastritis, Efstathios, Dimopoulos, Meletios Athanasios, Terzis, Gerasimos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065770/ https://www.ncbi.nlm.nih.gov/pubmed/33808154 http://dx.doi.org/10.3390/sports9040046

Ejemplares similares

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia
por: Gavriatopoulou, Maria, et al.
Publicado: (2017)

How I treat rituximab refractory patients with WM
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Cardiopulmonary Exercise Physiology in AL Amyloidosis Patients with Cardiac Involvement and Its Association with Cardiac Imaging Parameters
por: Briasoulis, Alexandros, et al.
Publicado: (2022)

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
por: Papanota, Aristea-Maria, et al.
Publicado: (2019)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
por: Fotiou, Despina, et al.
Publicado: (2020)

Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Lean Body Mass, Muscle Architecture, and Performance in Well-Trained Female Weightlifters
por: Zaras, Nikolaos, et al.
Publicado: (2020)

Monoclonal Gammopathy of Thrombotic Significance
por: Gkalea, Vasiliki, et al.
Publicado: (2023)

P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study
por: Spiliopoulou, Vassiliki, et al.
Publicado: (2022)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
por: Spiliopoulou, Vassiliki, et al.
Publicado: (2023)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Prevalence of MGCS Among Patients With Monoclonal Gammopathies
por: Theodorakakou, Foteini, et al.
Publicado: (2023)

Antibody Response to COVID-19 mRNA Vaccine in Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia after Primary Immunization and Booster: Reactivity to the Sars-Cov-2 WT Virus, Delta and Omicron Variants
por: Terpos, Evangelos, et al.
Publicado: (2022)

The extended 4-year follow-up results of the ELOQUENT-2 trial
por: Gavriatopoulou, Maria, et al.
Publicado: (2019)

Effect of Inter-Repetition Rest Vs. Traditional Resistance Training on The Upper Body Strength Rate of Force Development and Triceps Brachii Muscle Architecture
por: Zaras, Nikolaos, et al.
Publicado: (2022)

Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop
por: Bagratuni, Tina, et al.
Publicado: (2019)

Organ-specific manifestations of COVID-19 infection
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection
por: Orologas-Stavrou, Nikolaos, et al.
Publicado: (2020)

Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit
por: Liontos, Michalis, et al.
Publicado: (2021)

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Theodorakakou, Foteini, et al.
Publicado: (2021)

Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection
por: Kostopoulos, Ioannis V., et al.
Publicado: (2021)

Gastrocnemius Medialis Architectural Properties in Flexibility Trained and Not Trained Child Female Athletes: A Pilot Study
por: Panidi, Ioli, et al.
Publicado: (2020)

P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY
por: Malandrakis, Panagiotis, et al.
Publicado: (2023)

P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY
por: Terpos, Evangelos, et al.
Publicado: (2023)

P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
por: Terpos, Evangelos, et al.
Publicado: (2023)

Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology
por: Galani, Aikaterini, et al.
Publicado: (2021)

Treatment of Bing–Neel syndrome with first line sequential chemoimmunotherapy: A case report
por: Gavriatopoulou, Maria, et al.
Publicado: (2019)

Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
por: Rosati, Margherita, et al.
Publicado: (2022)

Changes in Muscle Power and Muscle Morphology with Different Volumes of Fast Eccentric Half-Squats
por: Zacharia, Evangelia, et al.
Publicado: (2019)

Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses
por: Georgakopoulou, Rebecca, et al.
Publicado: (2021)

Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
por: Kastritis, Efstathios, et al.
Publicado: (2023)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2018)

Emerging treatment strategies for COVID-19 infection
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
por: Kastritis, Efstathios, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4thq022d05bn4shhniliotso7m